Hypercholesterolemia

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

OneLegacy’s Community Wellness Event and Panel Inspired Hundreds of South LA Participants to Become Their Own Health Advocates

Retrieved on: 
Wednesday, March 6, 2024

Hundreds of local residents visited the Baldwin Hills Crenshaw Plaza this past Saturday to attend OneLegacy’s Connecting the Dots: Hip Hop & Health Community Event and Panel.

Key Points: 
  • Hundreds of local residents visited the Baldwin Hills Crenshaw Plaza this past Saturday to attend OneLegacy’s Connecting the Dots: Hip Hop & Health Community Event and Panel.
  • The event also included free haircuts, manicures, yoga and wellness sessions, COVID-19 tests, and fresh produce, followed by a health panel.
  • (Photo: Business Wire)
    The panel was moderated by impact Producer, Artepreneur, and HBCU graduate Maleena Lawrence and featured California Black Health Network’s Executive Director, Rhonda Smith, who shared vital information about African Americans and health.
  • Snow also participated in the panel, sharing their personal experiences with healthcare and promoting health advocacy among African Americans.

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Retrieved on: 
Thursday, February 15, 2024

CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).

Key Points: 
  • Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
  • The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024).
  • “Vaxxinity is committed to providing scalable, accessible, game-changing solution for worldwide heart health,” said Mei Mei Hu, CEO of Vaxxinity.
  • A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.

Valbiotis sets out its commercial and clinical roadmap for 2024

Retrieved on: 
Wednesday, January 17, 2024

In terms of clinical development, Valbiotis announces the launch of the HEART 2 study on TOTUM•070 (hypercholesterolemia) and the end of recruitment for the INSIGHT study on TOTUM•854 (arterial hypertension).

Key Points: 
  • In terms of clinical development, Valbiotis announces the launch of the HEART 2 study on TOTUM•070 (hypercholesterolemia) and the end of recruitment for the INSIGHT study on TOTUM•854 (arterial hypertension).
  • La Rochelle, January 16, 2024 (5:40 p.m. CET) – Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, sets out its roadmap for 2024.
  • Under this partnership with Nestlé Health Science, which includes an exclusive supply agreement, Valbiotis expects to receive its first TOTUM•63 order in the first half of 2024.
  • TOTUM•070 is now entering its final clinical phase: after obtaining the necessary approvals, the
    Phase II/III HEART 2 study is underway.

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

Retrieved on: 
Monday, January 8, 2024

Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.

Key Points: 
  • Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.
  • Potential initiation of a Phase III clinical trial for manfidokimab (IL-4R) for the treatment of moderate atopic dermatitis.
  • Over the next five years, Akeso has high expectations of launching around 10 internally developed blockbuster drugs, both in China and worldwide, thereby achieving successful commercialization.
  • Akeso has established and continuously advances its integrated and efficient system of discovery, development, production, and sales of its innovative drugs and pipeline candidates.

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Praluent, alirocumab, Date of authorisation: 23/09/2015, Revision: 21, Status: Authorised

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

Retrieved on: 
Sunday, November 12, 2023

BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. Treatment with VERVE-101 led to dose-dependent reductions of disease-causing low-density lipoprotein cholesterol (LDL-C) in people living with heterozygous familial hypercholesterolemia (HeFH), a life-threatening inherited disease characterized by lifelong elevations in blood LDL-C and accelerated atherosclerotic cardiovascular disease (ASCVD). VERVE-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C.

Key Points: 
  • The data showed that VERVE-101 could meaningfully and durably lower LDL-C in these patients.
  • The trial is designed to evaluate the safety and tolerability of VERVE-101, with additional analyses for pharmacokinetics and pharmacodynamic reductions in blood PCSK9 protein and LDL-C.
  • Initial safety data reported are from all ten patients enrolled as of a data cut-off date of October 16, 2023.
  • VERVE-102 is an in vivo base editing medicine that aims to inactivate the PCSK9 gene in a similar way to VERVE-101.